welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals announces last patient completes phase 3 trial protocol of CPP-1X/sul for familial adenomatous polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today the last patient has completed the study protocol in its pivotal Phase 3 trial of CPP-1X/sul for adults with familial adenomatous polyposis (FAP), a rare genetic disease that, if left untreated, progresses to colorectal cancer in nearly 100% of patients.
Analysis of the results from the randomized, double-blind trial are expected to be complete in early 2019, followed by potential submission of a New Drug Application (NDA) with the US Food and Drug Administration (FDA), which has granted CPP-1X/sul for the treatment of FAP fast track and orphan drug designation.
“Patients currently suffering from FAP have no effective treatments to delay or prevent progression of their disease,” said Carol A. Burke, MD, a gastroenterologist at the Cleveland Clinic and principal investigator for the FAP-310 clinical trial.
expertly curated content related to this topic
-
Levels of Rectal Mucosal Polyamines and Prostaglandin E2 Predict Ability of DFMO and Sulindac to Prevent Colorectal ...BACKGROUND & AIMS : Combination of p...
-
Prospective Randomized Study of Sulindac versus Calcium and Calciferol for Upper Gastrointestinal Polyps in Familial...Eighteen patients with familial adenomat...
-
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)The purpose of this phase III study is t...
-
Genetic Polymorphisms of Flavin Monooxygenase 3 in Sulindac-Induced Regression of Colorectal Adenomas in Familial Ad...Sulindac is a nonsteroidal antiinflammat...
-
Cancer Prevention Pharmaceuticals, Inc. and Tillotts Pharma AG Sign Licensing Agreement for CPP-1X/sulindac in Europ...Cancer Prevention Pharmaceuticals, Inc. ...
-
Genetic Polymorphisms of Human Flavin Monooxygenase 3 in Sulindac-Mediated Primary Chemoprevention of Familial Adeno...PURPOSE : Sulindac is a nonsteroidal ant...
-
Primary Chemoprevention of Familial Adenomatous Polyposis with SulindacBACKGROUND : Familial adenomatous polypo...